TNM stage Tumour grade Vascular invasion Tumour border configuration PTL infiltration Feature VEGFR1 pT stage pN stage Vascular invasion Post-operative therapy I+II III IV G1-2 G3 Absent Present PM IM Absent Present Baseline 1-unit increase pT1-2 pT3-4 pN0 pN1-2 Absent Present None Treated P-value 0.265 0.116 0.928 0.349 0.733 6.0 ± 21.0; 0.95 3.99 ± 13.4; 0.79 5.93 ± 19.7; 1.0 5.28 ± 18.3; 0.95 4.94 ± 18.1; 0.75 4.56 ± 16.8; 0.95 6.74 ± 21.4; 0.95 3.9 ± 15.7; 0.95 6.67 ± 20.7; 0.95 6.15 ± 20.1; 0.95 1.09 ± 1.5; 0.85 HR (95%CI) 1.009 (1.001-1.017) 1.0 1.0 1.0 1.0 5.67 (2.03-15.8) 4.81 (2.53-9.16) 2.82 (2.82-4.75) Eppenberger et al. BMC Cancer 2010, 10:93 http://www.biomedcentral.com/1471-2407/10/93 Table 3 VEGF-C/VEGFR3, VEGF-D/VEGFR2, and VEGF-D/VEGFR3 ratios and association with clinico-pathological features in mismatch repair-proficient colorectal cancer. VEGF-C/VEGFR3 VEGF-D/VEGFR2 VEGF-D/VEGFR3 Mean ± SD, median values. Kruskal-Wallis or Wilcoxon Rank Sum Test. PM = pushing/expanding margin; IM = infiltrating margin; PTL = peritumoral lymphocytic. Table 4 Multiple Cox regression analysis of VEGFR1 adjusting for T stage, N stage, vascular invasion as well as post- operative adjuvant therapy 1.8 ± 9.1; 1.0 0.94 ± 0.1; 1.0 4.67 ± 18.8; 1.0 2.46 ± 11.9; 1.0 0.96 ± 0.17; 1.0 2.2 ± 10.5; 1.0 2.34 ± 11.6; 1.0 1.82 ± 9.04; 1.0 2.53 ± 12.3; 1.0 1.96 ± 9.9; 1.0 3.18 ± 14.4; 1.0 P-value 0.024 <0.001 <0.001 <0.001 Page 7 of 10 P-value 0.981 0.317 0.158 0.437 0.575 P-value 0.55 0.274 0.53 0.172 0.538 6.6 ± 22.4; 1.03 13.2 ± 32.0; 1.05 7.14 ± 23.3; 1.05 8.34 ± 25.4; 1.05 11.9 ± 30.5; 1.0 8.75 ± 26.2; 1.0 9.7 ± 27.1; 1.05 7.62 ± 24.5; 1.0 10.5 ± 28.3; 1.05 10.6 ± 28.9; 1.0 1.79 ± 3.0; 1.05 1.0 1.0 1.0 1.0 1.0 HR (95%CI) 1.009 (1.001-1.017) 5.79 (2.07-16.19) 5.1 (2.61-9.97) 2.93 (1.71-5.02) 0.85 (0.49-1.48) P-value 0.032 <0.001 <0.001 <0.001 0.562